Related Experiment Videos
Comparative safety and tolerability of angiotensin II receptor antagonists
1Division of Hypertension and Vascular Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Insights
New angiotensin II receptor antagonists offer effective hypertension treatment with a favorable safety profile, similar to placebo. These drugs may become a first-line option for managing high blood pressure and preventing cardiovascular events.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Nephrology
Background:
- Hypertension is a prevalent condition and a significant risk factor for cardiovascular diseases like stroke and heart failure.
- Current antihypertensive medications can be limited by adverse effects during long-term use.
- The renin-angiotensin system plays a crucial role in blood pressure regulation.
Purpose of the Study:
- To review the safety and tolerability of angiotensin II receptor antagonists (ARBs) in hypertension management.
- To compare the efficacy and safety of ARBs with other established antihypertensive drug classes.
- To evaluate the potential of ARBs as a first-line treatment for hypertension.
Main Methods:
- Literature review of clinical studies and pharmacological research on ARBs.
- Analysis of data regarding blood pressure lowering efficacy.
- Assessment of safety and tolerability profiles, including adverse effects.
Main Results:
- Angiotensin II receptor antagonists are effective in lowering blood pressure, comparable to ACE inhibitors, calcium antagonists, beta-blockers, and diuretics.
- ARBs exhibit a favorable safety and tolerability profile, with no clear class-specific adverse effects identified.
- Their safety profile appears equivalent to that of placebo in clinical trials.
Conclusions:
- Angiotensin II receptor antagonists represent a specific and effective method for blocking the renin-angiotensin system.
- The favorable safety and tolerability of ARBs suggest they are a valuable option for hypertension treatment.
- ARBs have the potential to become a first-line therapy for hypertension, reducing target organ damage and cardiovascular morbidity/mortality.
Abstract:
Hypertension is a very common disease and represents a major risk factor for cardiovascular adverse events such as stroke and heart failure. In recent years, a big effort has been put into detecting and treating patients with hypertension. Several classes of drugs acting by different pharmacological mechanisms can be chosen for the treatment of hypertension. However, the long term use of all anti-hypertensive agents is sometimes limited by the occurrence of adverse effects. Thanks to continuous pharmacological research, new compounds are regularly developed and become available in clinical practice. Recently, several new, nonpeptide, orally active angiotensin II receptor antagonists have reached the market. Today, these substances represent the most specific way to block the renin angiotensin system. Numerous studies have now demonstrated that these angiotensin II antagonists are as effective as ACE inhibitors, calcium antagonists, beta-blockers or diuretics in lowering blood pressure in patients with hypertension. Given the increasing use of angiotensin II receptor antagonists in the treatment of hypertension, it is important to review their safety and tolerability. Based on the actual level of knowledge, the striking feature of this class of agents is their favourable safety and tolerability profile which appears to be equivalent to that observed with placebo. Indeed, so far, no clear class-specific adverse effect has been attributed to the angiotensin II receptor antagonists. Thus, if angiotensin II antagonists prevent target organ damage and reduce the morbidity and mortality of patients with hypertension, they may well become a first-line treatment of hypertension.